ICCC
IMMUCELL CORP /DE/
$9.70
+0.94%
$88.4M
No data for this timeframe.
Vol
Market Cap$88.4M
Cap SizeMicro Cap
Inst. Holders5 funds
Inst. Value$3.6M
Inst. Activity0 buys / 1 sells
SEC Reports4
Press Releases1
Exchange Nasdaq·Sector In Vitro & In Vivo Diagnostic Substances·Inc. DE·CIK 0000811641·Prev Close $9.61
Recent Activity
May 14, 2026
earnings
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026
<p>PORTLAND, Maine, May 14, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCe
May 8, 2026
SEC
ImmuCell and Norbrook signed a Settlement Deed resolving claims from a 2019 agreement; Norbrook pays ImmuCell $2M. The s
8-K — Impact 4/10
Apr 21, 2026
SEC
ImmuCell reported a 28.4% year-over-year increase in preliminary, unaudited product sales for Q1 2026, reaching $10.4 mi
8-K — Impact 7/10
Apr 15, 2026
Insider
Wainman Paul R sold 11,933 shares
Director @ $0.00 ($0.00)
Apr 15, 2026
Insider
Basse Gloria F sold 11,933 shares
Director @ $0.00 ($0.00)
Apr 15, 2026
Insider
Tomsche David Scott sold 11,933 shares
Director @ $0.00 ($0.00)
Apr 8, 2026
SEC
ImmuCell reported preliminary Q1 2026 sales of $10.4M, up 28.4% YoY, driven by a 38.5% surge in Tri-Shield® sales. Inter
PRESS-RELEASE — Impact 6/10
Inst.
UBS Group AG — NEAR_EXIT
1,000 shares ($6.3K)
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jul 13, 2020 | Aegis Capital | INITIATE | Buy |
Latest Reports
BULLISH
8-K
4/10
ImmuCell and Norbrook signed a Settlement Deed resolving claims from a 2019 agreement; Norbrook pays ImmuCell $2M. The s
May 8, 2026
BULLISH
8-K
7/10
ImmuCell reported a 28.4% year-over-year increase in preliminary, unaudited product sales for Q1 2026, reaching $10.4 mi
Apr 21, 2026
MIXED
Press
6/10
ImmuCell reported a 4.3% increase in 2025 product sales to $27.6 million and a significant improvement in gross margin t
Mar 4, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $1.9M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $926.7K | — |
| MORGAN STANLEY | $767.0K | ADD |
| BANK OF AMERICA CORP | $12.5K | — |
| WELLS FARGO & COMPANY/MN | $4.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 15, 2026 | Wainman Paul | A | $0.00 |
| Apr 15, 2026 | Basse Gloria | A | $0.00 |
| Apr 15, 2026 | Tomsche David | A | $0.00 |
| Apr 15, 2026 | Turner Kathy | A | $0.00 |
| Mar 20, 2026 | BRIGHAM MICHAEL | F | $146.0K |
5 institutional holders with $3.6M total value (580,442 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 302,996 | $1.9M | 52.2% | ADD +36.8% |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 150,689 | $926.7K | 26.0% | — |
| 3 | MORGAN STANLEY | 124,716 | $767.0K | 21.5% | ADD +36.4% |
| 4 | BANK OF AMERICA CORP /DE/ | 2,040 | $12.5K | 0.4% | — |
| 5 | WELLS FARGO & COMPANY/MN | 1 | $4.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | NEAR_EXIT | 8,391 | 1,000 | -88.1% | $6.3K | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 225,595 | 308,702 | +36.8% | $2.1M | 2025-Q2 |
| MORGAN STANLEY | ADD | 76,916 | 104,916 | +36.4% | $730.2K | 2025-Q2 |
| UBS Group AG | TRIM | 16,891 | 8,391 | -50.3% | $58.4K | 2025-Q2 |
| UBS Group AG | ADD | 12,580 | 16,891 | +34.3% | $80.9K | 2025-Q1 |
| CITADEL ADVISORS LLC | NEW | — | 29,021 | — | $149.5K | 2024-Q4 |
9 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 15, 2026 | Wainman Paul R | Director | A | 11,933 | $0.00 | $0.00 |
| Apr 15, 2026 | Basse Gloria F | Director | A | 11,933 | $0.00 | $0.00 |
| Apr 15, 2026 | Tomsche David Scott | Director | A | 11,933 | $0.00 | $0.00 |
| Apr 15, 2026 | Turner Kathy V | Director | A | 17,899 | $0.00 | $0.00 |
| Mar 20, 2026 | BRIGHAM MICHAEL F | Director | F | 24,052 | $6.07 | $146.0K |
| Mar 20, 2026 | BRIGHAM MICHAEL F | Director | M | 25,000 | $0.00 | $0.00 |
| Mar 20, 2026 | BRIGHAM MICHAEL F | Director | M | 25,000 | $5.84 | $146.0K |
| Jan 27, 2026 | te Boekhorst Paul Francis Olivier | President and CEO | A | 109,500 | $0.00 | $0.00 |
| Apr 16, 2025 | Basse Gloria F | Director | A | 10,000 | $0.00 | $0.00 |
| Apr 16, 2025 | Rosgen Steven T. | Director | A | 10,000 | $0.00 | $0.00 |
| Apr 16, 2025 | Brockmann Bobbi Jo | VP of Sales and Marketing | A | 5,000 | $0.00 | $0.00 |
| Apr 16, 2025 | Tomsche David Scott | Director | A | 10,000 | $0.00 | $0.00 |
| Apr 16, 2025 | Wainman Paul R | Director | A | 10,000 | $0.00 | $0.00 |
| Apr 16, 2025 | Gathagan Bryan K. | Director | A | 10,000 | $0.00 | $0.00 |
4 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 2 mixed, 0 neutral. Avg impact: 5.8/10.
BULLISH
8-K
4/10
ImmuCell and Norbrook signed a Settlement Deed resolving claims from a 2019 agreement; Norbrook pays
May 8, 2026
BULLISH
8-K
7/10
ImmuCell reported a 28.4% year-over-year increase in preliminary, unaudited product sales for Q1 202
Apr 21, 2026
MIXED
PRESS-RELEASE
6/10
ImmuCell reported preliminary Q1 2026 sales of $10.4M, up 28.4% YoY, driven by a 38.5% surge in Tri-
Apr 8, 2026
MIXED
8-K
6/10
ImmuCell Corporation reported unaudited financial results for 2025, showing a 4.3% increase in produ
Mar 4, 2026
Historical analyst distribution (last covering-analyst action Jul 2020): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2021-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2021-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jul 13, 2020 | Aegis Capital | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Dec 1, 2021 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Nov 1, 2021 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Oct 1, 2021 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Sep 1, 2021 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 14, 2026
earnings
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026
<p>PORTLAND, Maine, May 14, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics
May 14, 2026
earnings_calendar
ICCC Q1 2026 Earnings Scheduled — 2026-05-14
May 7, 2026
earnings
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026
Conference Call Scheduled for Friday, May 15, 2026 at 9:00 AM ET <pre>Conference Call Scheduled for Friday, May 15, 2026 at 9:00 AM ET</pre>
Apr 13, 2026
other
ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors
<p>PORTLAND, Maine, April 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics
Apr 8, 2026
earnings
ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results
<p>PORTLAND, Maine, April 08, 2026 (GLOBE NEWSWIRE) -- <strong>ImmuCell Corporation (Nasdaq: ICCC) </strong>(“ImmuCell” or the “Company”), an animal
Mar 18, 2026
other
ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board
<p>PORTLAND, Maine, March 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics
Mar 4, 2026
earnings
ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025
<p>PORTLAND, Maine, March 04, 2026 (GLOBE NEWSWIRE) -- <strong>ImmuCell Corporation (Nasdaq: ICCC) </strong>(“ImmuCell” or the “Company”), an animal
Mar 4, 2026
earnings_calendar
ICCC Q4 2025 Earnings After Market Close — 2026-03-04